Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

Adults with unresectable stage III or IV melanoma maintained similar progression-free disease control with 1- or 2-year ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by ...

Investing.com -- Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...